BPC-157 10mg

Compound Name: BPC-157
Synonyms: Body protection compound 15, Bepecin, Bpc 15
CAS Number: 137525-51-0
Molecular Formula: C₆₂H₉₈N₁₆O₂₂
Molecular Weight: ~1419.5 g/mol
Structure: Synthetic 15-amino acid linear peptide
Peptide Sequence: H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH

Chemical Structure:

Source: PubChem

Mechanism of Action: BPC-157 modulates molecular pathways involved in tissue repair, including upregulation of VEGFR2 signaling and modulation of nitric oxide release. It has been shown to influence the expression of genes involved in angiogenesis (e.g., egr-1), stabilize endothelial integrity, and facilitate the recruitment of fibroblasts to injury sites. The peptide’s activity does not require a delivery vehicle and is preserved across oral, intraperitoneal, and topical administration routes.

Biological Activity: In vivo studies have demonstrated that BPC-157 enhances tendon and ligament healing by improving collagen organization, increasing tensile strength, and reducing histological markers of inflammation. Additionally, it exhibits protective effects against oxidative stress and has been shown to restore integrity to damaged vasculature and gastrointestinal tissues.

Storage: Store lyophilized peptide at ?20°C; protect from moisture and light. Reconstituted solutions should be stored at 2–8°C and used within 30 days.

Drug Categories: Amino Acids, Peptides, and Proteins

Additional Notes:

• Demonstrates remarkable peptide stability in gastric juice (?24 hours)
• Water-soluble at neutral pH
• Not approved for human or veterinary use

Summary Table:

Disclaimer: For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.

Detailed Product Description

BPC-157 is a 15-mer synthetic peptide fragment of a protein component of human gastric juice. It has been extensively studied in animal models for its regenerative effects across multiple tissue types, including tendon, ligament, vascular endothelium, muscle, and intestinal mucosa. Mechanistically, BPC-157 appears to function through nitric oxide-mediated vasodilation, angiogenic factor regulation, and recruitment of fibroblasts and endothelial progenitor cells. It also reduces leukocyte infiltration and oxidative stress markers following injury. Its ability to remain chemically intact in gastric conditions facilitates its use via oral, parenteral, or topical administration.

Research Highlights

• Ligament and Tendon Healing: BPC-157 enhances biomechanical properties and collagen fiber organization in transected Achilles tendons and medial collateral ligaments in rodent models.
• Angiogenesis and Endothelial Protection: The peptide promotes neovascularization by upregulating VEGFR2 and egr-1 pathways while stabilizing endothelial integrity under oxidative or inflammatory stress.
• Systemic Stability and Delivery Versatility: BPC-157 retains full biological activity after exposure to gastric juice and demonstrates efficacy via multiple administration routes without requiring a carrier vehicle.

Mechanism of Action

BPC-157 is a synthetic pentadecapeptide that demonstrates potent regenerative activity across a range of tissues. While it does not bind a single known receptor, it modulates several receptor-linked signaling systems, particularly VEGFR2 and NO synthase-linked pathways, with downstream effects on angiogenesis, inflammation, and cellular repair.

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Modulation

• Enhances VEGFR2 expression and downstream angiogenesis: BPC-157 induces rapid angiogenesis in granulation tissue via VEGFR2-associated mechanisms, promoting organized capillary formation and increased vascular density in wound regions.
• Supports endothelial cell proliferation and migration: VEGFR2 modulation is associated with increased fibroblast activity and early connective tissue regeneration in transected ligament models.

Nitric Oxide Synthase (eNOS/iNOS) Pathway Regulation

• Stimulates NO production through eNOS/iNOS activation: BPC-157 upregulates nitric oxide synthesis in vascular tissue and restores endothelial homeostasis, as shown in ischemic and inflammatory models.
• Restores vasomotor tone: Normalizes blood pressure in models of both pharmacologically induced hypotension and hypertension.
• Reduces oxidative injury: Attenuates lipid peroxidation and inflammatory oxidative stress through NO-linked mechanisms.

Pharmacokinetic Profile:

• Route of Administration: Intraperitoneal, subcutaneous, oral, topical
• Dosing Frequency: Undetermined in humans
• Half-Life: Not clinically established; bioactive >24h in gastric environments

Formulation & Handling

• Supplied as a sterile lyophilized powder.
• Reconstitute with sterile water or saline (0.9%) under aseptic conditions.
• Do not expose to repeated freeze–thaw cycles. Protect from light and moisture.
• Use within 30 days after reconstitution and store at 2–8°C.

Selected Clinical Trial Activity

References

Gjurasin, M. et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul. Pept. 160, 33–41 (2010).

Staresinic, M. et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocyte growth. J. Orthop. Res. 21, 976–983 (2003).

Cerovecki, T. et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J. Orthop. Res. 28, 1155–1161 (2010).

Sikiric, P. The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology 7, 1–14 (1999).